A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
A phase 2 trial of TQB2102 in HER2-positive breast cancer, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., active and no longer recruiting.
Overview
A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer is a phase 2 interventional study registered as NCT06198751 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 104 participants enrolled, started 2024-02-05 and due to reach its primary completion in 2025-05-08. Interventions recorded: 6.0 mg/kg of TQB2102 for injection and 7.5 mg/kg of TQB2102 for injection.
Similar pages
not linked directly; found by shared links- TrialThe Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
- TrialA Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
- TrialClinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
- TrialA Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing), HER2-positive breast cancer.
- TrialClinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing), HER2-positive breast cancer.
- TrialA Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing), HER2-positive breast cancer.
- TrialTQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing), HER2-positive breast cancer and the tag pipeline.
- TrialA Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.